Supernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Supernus Pharma (SUPN) Tops Q2 EPS by 14c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
August 7, 2018 4:30 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.57, $0.14 better than the analyst estimate of $0.43. Revenue for the quarter came in at $99.5 million versus the consensus estimate of $99.86 million.
Total revenue of $99.5 million, a 31% increase over 2017Net product sales of $97.0 million, a 32% increase over... More